Syfovre – Treatment for Dry Macular Degeneration

There’s exciting news for patients with dry macular degeneration in the Venice, North Port and Englewood areas of Florida! They now have access to Syfovre, an innovative and effective treatment for dry AMD that has recently been approved by the FDA.

An Innovative Treatment for Dry Macular Degeneration in Venice, FL

The recent FDA approval of the innovative new drug, Syfovre, marks a major milestone in the treatment of dry age-related macular degeneration (AMD). This groundbreaking treatment has the potential to prevent blindness in millions of Americans who would otherwise lose their sight to this progressive disease. If you or someone you know is experiencing vision loss due to macular degeneration in Venice, FL, we encourage you to learn more about this life-changing treatment and schedule a consultation with us.

Syfovre - A new treatment for dry macular degeneration for patients in Venice FL and surrounding areas of North Port and Englewood

How Dry Macular Degeneration Leads to Vision Loss

Dry macular degeneration is a major cause of vision loss, particularly for people over the age of 50. According to the National Eye Institute, an estimated 11 million people in the United States are affected by some form of macular degeneration, with dry macular degeneration accounting for around 90% of all cases. As the population ages, the prevalence of this progressive disease is expected to increase.

Dry macular degeneration can affect individuals in different ways, with the severity and speed of vision loss varying widely between individuals. Intermediate cases may have difficulty with reading or driving that gradually worsens over time. Patients with advanced dry macular degeneration may experience expanding blind spots in their central vision, which can significantly impact daily activities. In some cases, the disease can lead to severe vision loss or even blindness.

Until recently, medical interventions for dry macular degeneration were primarily focused on prevention and the use of low vision aids. Here’s a summary of these recommendations:

  1. Making lifestyle changes such as quitting smoking, maintaining a healthy diet and exercise routine, and managing any underlying health conditions to help reduce the risk of macular degeneration.
  2. Using a combination of vitamins C and E, Lutein, Zeaxanthin, zinc, and copper together was found to slow down the progression of the disease in patients with intermediate or advanced dry macular degeneration by the second Age-Related Eye Disease Study (AREDS2).
  3. The use of low vision aids such as magnifying glasses, telescopes, and computer software can help people with macular degeneration to perform daily activities more easily.
Different Stages of Dry Macular Degeneration

As dry macular degeneration progresses, retinal atrophy can cause expanding blind spots in the central vision.

How normal vision compares with dry macular degeneration

Dry macular degeneration can have a significant impact on critical life activities such as reading, driving, and recognizing faces.

Syfovre: A Game-Changing FDA-Approved Treatment for Dry Macular Degeneration

In a significant development for those with dry age-related macular degeneration (AMD), the FDA has approved a new medication called Syfovre. Syfovre is an inhibitor of complement, a component of the body’s immune system that plays a crucial role in the progression of macular degeneration. Scientists first noticed the link between complement and dry AMD during genetic testing on patients with the condition, with those carrying mutations in the genes for complement at higher risk for blindness.

Several complement inhibitors have been in development since the discovery of complement’s role in dry AMD, with many currently undergoing testing. However, Syfovre has become the first to receive FDA approval for use in patients. Syfovre has been shown to reduce the growth of blind spots in advanced dry macular degeneration by approximately 20% over two years, with many patients able to retain their ability to read or drive as a result of the medication. With the approval of Syfovre, patients now have a promising new treatment option for managing the impact of dry AMD on their vision.

Retinal atrophy, a common symptom of advanced dry macular degeneration, causing blind spots in central vision

Retinal atrophy, a common symptom of advanced dry macular degeneration, can cause the development of blind spots near the central vision.

If you have been diagnosed with dry macular degeneration, contact us today to explore these exciting new treatment options that can help maintain your vision and improve your quality of life.

How Syfovre Works & Potential Side Effects

Syfovre is delivered via injection into the eye every 1-2 months, offering a promising new treatment for dry age-related macular degeneration. While the most commonly reported side effects are mild, Syfovre and other complement inhibitors are known to increase the risk of developing leakage or bleeding in the retina, a condition known as wet AMD. Over two years, 7-12% of patients receiving Syfovre injections developed wet AMD, compared to 3% of those who did not receive the treatment. Despite this risk, excellent treatments are available for wet age-related macular degeneration, and with proper monitoring and care, patients can receive the benefits of Syfovre with minimal concern.

Complement Inhibitors: The Future of Dry AMD Treatment

In addition to Syfovre, other complement inhibitors are currently in various stages of development. Zimura is a new medication with the potential to treat dry age-related macular degeneration and is expected to seek FDA approval soon. As we gain more experience with these new medications there is hope that incremental improvements in strength and efficacy will lead to more effective treatment options for patients with dry AMD. Complement inhibitors represent an exciting area of advancement in ophthalmology and have the potential to transform the way we manage dry macular degeneration and produce better outcomes.

New Classes and Future Treatments for Dry Macular Degeneration


Neuroprotectants are drugs that protect retina cells from damage and slow the progression of dry age-related macular degeneration. Ciliary neurotrophic factor (CNTF), a protein that promotes the survival and growth of neurons in the retina, is one of the neuroprotective agents currently being studied for this purpose. Others are also being researched. These treatments have the potential to have a major impact on outcomes and the quality of life of patients with dry AMD.

Inflammation-Reducing Medications

Inflammation is believed to be a key factor in the development and progression of dry age-related macular degeneration. To combat this, inflammation-reducing medications are designed to reduce inflammation in the retina and slow down the progression of the disease over time.

Patient Testimonials

Dr Shane is everything you’d expect in a health care provider. She and her entire staff are very compassionate, knowledgeable, and thorough. I’m confident that I got the best doctor to treat my condition. How lucky we are to have someone with her credentials here in Venice!

Karen Parker, Google Review

Contact Venice Retina for Syfovre Treatments Today!

The recent FDA approval of Syfovre and other new medications marks a significant milestone in the fight against dry age-related macular degeneration, bringing hope to millions of people at risk of vision loss, including those in Venice, Florida and nearby areas of North Port and Englewood. If you or someone you know has been diagnosed with dry macular degeneration, it’s important to speak with a specialist about the latest treatment options. At Venice Retina, we offer the newest and most effective treatments for macular degeneration along with compassionate care to the residents of the Southwest region of Florida.

Syfovre Treatments for Dry macular degeneration in Venice North Port and Englewood Florida with Dr. Anita Shane of Venice Retina